In this study, we established a serum EphA2-NF quantitative analysis system, which was used to evaluate the potential of EphA2-NF as a new biomarker for early pancreatic cancer diagnosis and prediction of therapy response using sera from independent testing and validation cohorts. This evidence concerns the gene EPHA2 and pancreatic neoplasm.